第48届圣安东尼奥乳腺癌研讨会（SABCS 2025）将于当地时间2025年12月9-12日在美国得克萨斯州圣安东尼奥Henry B.Gonzalez Convention Center举行。作为乳腺癌领域的顶级盛会，SABCS聚焦乳腺癌生物学、病因、预防、诊断及治疗前沿，促进临床、转化与基础研究的深度融合，为全球科研人员提供交流协作与专业成长的平台。肿瘤瞭望-乳腺时讯特对会议第二天（12月10日）内容进行梳理，涵盖全体大会、Mini口头报告、海报聚焦专场、海报展示、教育专场及职业发展论坛等，并将全体大会1（General Session 1）及Mini口头报告（Rapid Fire 6和Rapid Fire 3）题目进行整理，以便读者快速了解会议动态，敬请关注后续详细报道！
编者按：第48届圣安东尼奥乳腺癌研讨会（SABCS 2025）将于当地时间2025年12月9-12日在美国得克萨斯州圣安东尼奥Henry B.Gonzalez Convention Center举行。作为乳腺癌领域的顶级盛会，SABCS聚焦乳腺癌生物学、病因、预防、诊断及治疗前沿，促进临床、转化与基础研究的深度融合，为全球科研人员提供交流协作与专业成长的平台。肿瘤瞭望-乳腺时讯特对会议第二天（12月10日）内容进行梳理，涵盖全体大会、Mini口头报告、海报聚焦专场、海报展示、教育专场及职业发展论坛等，并将全体大会1（General Session 1）及Mini口头报告（Rapid Fire 6和Rapid Fire 3）题目进行整理，以便读者快速了解会议动态，敬请关注后续详细报道！
四场海报聚焦专场：1、海报聚焦1：应对乳腺癌差异性与治疗相关毒性；2、海报聚焦2：早期与晚期肿瘤的分子进化；3、海报聚焦3：转移性乳腺癌中CDK抑制剂与抗体药物偶联物耐药的新兴模式；4、海报聚焦4：风险、遗传学与临床结局。
两场全体大会专场：1、开幕致辞；2、全体大会1。
一场颁奖讲座：William L.McGuire Award Lecture纪念讲座奖
一场案例讨论：临床病例讨论
两场海报展示：1、Poster Session 1；2、Poster Session 2。
两场Mini口头报告：1、Rapid Fire 6；2、Rapid Fire 3。
一场前沿进展专场——最新进展1：为乳腺癌的适应性治疗细化风险和个体化治疗液体活检
一场特殊专场：乳腺癌家庭登记：过去、现在和未来
一场辩论专场——转化争议：ADCs、靶向治疗还是化疗？
五场教育专场：1、教育专场10：罕见肿瘤类型；2、教育专场6：ADC药物的临床实践；3、教育专场7：肿瘤免疫微环境；4、教育专场8：低风险HR+早期乳腺癌的优化降阶治疗；5、教育专场9：遗传易感基因携带者的管理策略。
一场职业发展论坛：妇女职业发展工作坊
专场：General Session 1
时间：12月10日9:30 AM–12:00 PM CST
地点：Hall 1
摘要号：GS1-01
Her2climb-05:a randomized，double-blind，phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+metastatic breast cancer
Her2climb-05：一项随机、双盲、三期研究，比较图卡替尼与安慰剂联合曲妥珠单抗和帕妥珠单抗作为HER2+转移性乳腺癌的维持治疗
讲者：Erika Hamilton，Sarah Cannon Research Institute，Nashville，TN
摘要号：GS1-04
Adjuvant aromatase inhibitor or tamoxifen in patients with hormone receptor-positive/HER2-positive early breast cancer:an exploratory analysisfrom the ALTTO(BIG 2-06)trial
辅助芳香化酶抑制剂或他莫昔芬治疗HR+/HER2+早期乳腺癌：来自ALTTO（BIG 2-06）研究的探索性分析
讲者：Matteo Lambertini，University of Genova–IRCCS Ospedale Policlinico San Martino，Genoa，Italy
摘要号：GS1-05
Tumor infiltrating lymphocytes(TILs)and pathologic complete response(pCR)in stage II/III HER2+breast cancer treated with taxane，trastuzumab，and pertuzumab(THP):secondary results from the ECOG-ACRIN-1181/CompassHER2 pCR trial
紫杉烷、曲妥珠单抗和帕妥珠单抗（THP）治疗II/III期HER2+乳腺癌的肿瘤浸润淋巴细胞（TILs）和病理完全缓解（pCR）：ECOG-ACRIN-1181/CompassHER2 pCR研究的次要结果
讲者：Sunil S Badve，Emory School of Medicine，Atlanta，GA
摘要号：GS1-06
Prognostic and predictive associations of manual，digital and AI-derived tumor infiltrating lymphocytes-scoring:A retrospective analysis from the Phase III APHINITY trial
人工、数字化及人工智能评估肿瘤浸润淋巴细胞评分的预后与预测关联：一项基于III期APHINITY研究的回顾性分析
讲者：Roberto Salgado，Peter MacCallum Cancer Centre，Melbourne，Australia
摘要号：GS1-07
Circulating tumor DNA(ctDNA)in human epidermal growth factor receptor 2-positive(HER2[+])Early Breast Cancer(EBC):Translational analysis of PHERGain neoadjuvant tailored treatment study
针对人类表皮生长因子受体2阳性（HER2+）早期乳腺癌（EBC）的循环肿瘤DNA（ctDNA）分析：PHERGain新辅助个体化治疗研究的转化性分析
讲者：Antonio Llombart-Cussac，Hospital Arnau de Vilanova;Translational Oncology Group，Facultad de Ciencias de la Salud，Universidad Cardenal Herrera-CEU;Medica Scientia Innovation Research(MedSIR)，Valencia，Spain
摘要号：GS1-09
Multimodal Artificial Intelligence(AI)Models Integrating Image，Clinical，and Molecular Data for Predicting Early and Late Breast Cancer Recurrence in TAILORx
整合影像、临床与分子数据的多模态人工智能（AI）模型在TAILORx研究中预测乳腺癌早期与晚期复发的研究
讲者：Joseph A Sparano，Icahn School of Medicine at Mount Sinai，New York，NY
摘要号：GS1-10
Sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+/HER2−(IHC 0，1+，2+/ISH−)metastatic breast cancer:Primary results from ASCENT-07
ASCENT-07研究主要结果：在HR+/HER2-（IHC 0，1+，2+/ISH−）转移性乳腺癌中，内分泌治疗后首次使用SG与化疗的疗效对比
讲者：Komal L.Jhaveri，Memorial Sloan Kettering Cancer Center(MSKCC);Weill Cornell Medical College，New York，NY
专场：Rapid Fire 6
时间：12月10日1:00 PM–2:00 PM CST
地点：Stars at Night 1-2
摘要号：RF6-01
Trastuzumab deruxtecan(T-DXd)vs trastuzumab emtansine(T-DM1)in patients with high-risk human epidermal growth factor receptor 2-positive(HER2+)primary breast cancer(BC)with residual invasive disease after neoadjuvant therapy:Interim analysis of DESTINY-Breast05
德曲妥珠单抗（T-DXd）vs恩美曲妥珠单抗（T-DM1）用于治疗新辅助治疗后存在残留浸润病灶的高风险人表皮生长因子受体2阳性（HER2+）原发性乳腺癌患者：DESTINY-Breast05研究中期分析
讲者：Sibylle Loibl，GBG Neu-Isenburg and Goethe University，Neu-Isenburg，Germany
摘要号：RF6-02
DESTINY-Breast11(DB-11)safety:neoadjuvant trastuzumab deruxtecan(T-DXd)alone or followed by paclitaxel+trastuzumab+pertuzumab(THP)vs dose-dense doxorubicin+anthracycline followed by THP(ddAC-THP)in high-risk，HER2+early-stage breast cancer(eBC)
DESTINY-Breast11研究中患者的安全性：在高风险HER2阳性早期乳腺癌中，新辅助T-DXd单药治疗序贯紫杉醇+曲妥珠单抗+帕妥珠单抗（THP）对比剂量密集多柔比星+环磷酰胺序贯THP方案的安全性
讲者：Giuseppe Curigliano，Division of Early Drug Development for Innovative Therapies，European Institute of Oncology，IRCCS&Department of Oncology and Hematology-Oncology，University of Milano，Milano，Italy
摘要号：RF6-03
Efficacy and safety of DP303c versus T-DM1 in HER2-positive advanced breast cancer:Interim analysis of a randomized，open-label，phase 3 trial
DP303c vs T-DM1治疗HER2阳性晚期乳腺癌的疗效和安全性：一项随机、开放标签3期试验的中期分析
讲者：李惠平（北京大学肿瘤医院）
摘要号：RF6-04
Associations Between Cardiac Radiation Dose Volume Metrics and Cardiac Specific Health Related Quality of Life for Patients with Breast Cancer Randomized to Proton versus Photon Radiation on the RadComp Trial
RadComp试验中随机接受质子与光子放疗的乳腺癌患者心脏放射剂量体积参数与心脏特异性健康相关生活质量的关联
讲者：Jean L Wright，University of North Carolina，Chapel Hill，NC
摘要号：RF6-05
Patient-reported outcomes(PROs)with sacituzumab govitecan(SG)vs chemotherapy in patients with previously untreated advanced triple-negative breast cancer(TNBC)who are not candidates for PD-(L)1 inhibitors in the phase 3 ASCENT-03 study
3期ASCENT-03研究中，既往未经治疗且不适合PD-（L）1抑制剂治疗的晚期三阴性乳腺癌患者使用戈沙妥珠单抗对比化疗治疗的患者报告结局（PROs）
讲者：Kevin Punie，Oncology Center Antwerp，Ziekenhuis aan de Stroom，Antwerp，Belgium
摘要号：RF6-06
Patient-reported outcomes(PROs)in DESTINY-Breast11:neoadjuvant treatment(NAT)with trastuzumab deruxtecan(T-DXd)alone or followed by paclitaxel+trastuzumab+pertuzumab(THP)vs dose-dense doxorubicin+anthracycline followed by THP(ddAC-THP)in high-risk，HER2+early-stage breast cancer(eBC)
DESTINY-Breast11研究中的患者报告结局（PROs）：在高风险HER2阳性早期乳腺癌中，新辅助T-DXd单药治疗序贯紫杉醇+曲妥珠单抗+帕妥珠单抗（THP）对比剂量密集多柔比星+环磷酰胺序贯THP方案的疗效
讲者：Shanu Modi，Department of Medicine，Breast Medicine Service，Memorial Sloan Kettering Cancer Center，New York，NY
摘要号：RF6-07
Trastuzumab deruxtecan(T-DXd)+pertuzumab(P)vs taxane+trastuzumab+pertuzumab(THP)for first-line(1L)treatment of patients(pts)with HER2-positive(HER2+)advanced/metastatic breast cancer(a/mBC):patient-reported outcomes(PROs)from the DESTINY-Breast09 study
T-DXd+帕妥珠单抗（P）vs THP用于HER2阳性晚期/转移性乳腺癌患者的一线治疗：DESTINY-Breast09研究的患者报告结局（PROs）
讲者：Mothaffar Rimawi，Dan L Duncan Comprehensive Cancer Center，Baylor College of Medicine，Houston，TX
专场：Rapid Fire 3
时间：12月10日4:30 PM–5:30 PM CST
地点：Stars at Night 1-2
摘要号：RF3-01
Clinical outcomes of invasive lobular carcinoma(ILC)versus non-lobular breast cancer(NLC)assessed by expert pathologists，an artificial intelligence(AI)CDH1 classifier，and AI-derived tumor microenvironment(TME)biomarkers in TAILORx
在TAILORx研究中，由病理学专家、人工智能CDH1分类器及AI衍生的肿瘤微环境生物标志物评估的浸润性小叶癌与非小叶型乳腺癌的临床结局
讲者：Roberto Salgado，Peter MacCallum Cancer Centre，Melbourne，Australia
摘要号：RF3-02
Gene Expression-based Subtyping of Early Triple-Negative Breast Cancer(TNBC)for Prediction of Response to Neoadjuvant Immune-chemotherapy in the NSABP B-59/GBG-96-GeparDouze Trial
基于基因表达的早期三阴性乳腺癌分型用于预测NSABP B-59/GBG-96-GeparDouze研究中新辅助免疫化疗的疗效
讲者：Carsten Denkert，Philipps-University Marburg and University Hospital Marburg(UKGM)，Marburg，Germany
摘要号：RF3-03
Evaluation of a digital pathology based multimodal artificial intelligence model for prognosis and prediction of chemotherapy benefit in node-negative，hormone receptor-positive breast cancer patients:analysis of the NSABP B-20 trial.
评估基于数字病理学的多模态人工智能模型对淋巴结阴性、激素受体阳性乳腺癌患者预后及化疗获益的预测价值：NSABP B-20研究分析
讲者：Charles E Geyer，NSABP Foundation and UPMC Hillman Cancer Center，Pittsburgh，PA，Pittsburgh，PA
摘要号：RF3-04
Tumor-informed circulating tumor DNA analysis to assess molecular residual disease for prognosis and prediction of benefit from palbociclib in the PALLAS trial
在PALLAS试验中，基于肿瘤信息的循环肿瘤DNA分析用于评估分子残留病的预后，并预测哌柏西利的获益
讲者：Heather A Parsons，Fred Hutchinson Cancer Center，Seattle，WA
摘要号：RF3-05
Tissue-free circulating tumour DNA detection in patients with early triple negative breast cancer from the c-TRAK-TN trial
c-TRAK-TN研究中早期三阴性乳腺癌患者的无创循环肿瘤DNA检测
讲者：Niamh Cunningham，Royal Marsden Hospital，London，United Kingdom
摘要号：RF3-06
Tumor infiltrating lymphocytes in post-NACT residual tumors in ECOG-ACRIN EA1131–impact of intrinsic subtypes.
ECOG-ACRIN EA1131研究中新辅助化疗后残留肿瘤中的肿瘤浸润淋巴细胞——内在亚型的影响
讲者：Sunil S Badve，Emory School of Medicine，Atlanta，GA
摘要号：RF3-07
A Multimodal-Multitask Deep Learning Model Trained in NSABP B-42 and Validated in TAILORx for Late Distant Recurrence Risk in HR+Early Breast Cancer
在NSABP B-42中训练并在TAILORx中验证的用于预测HR+早期乳腺癌远期远处复发风险的多模态-多任务深度学习模型
讲者：Eleftherios Mamounas，National Surgical Adjuvant Breast and Bowel Project and AdventHealth Cancer Institute，Orlando，FL
京公网安备 11010502033352号